+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia

Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia

Current Pharmaceutical Biotechnology 13(8): 1535-1542

The treatment of schizophrenia has been focused on modulation of dopamine receptors for over 50 years. Recent developments have implicated other neurotransmitter systems in the pathophysiology of this illness. The discovery and characterization of glutamate receptors and their roles in the brain has lead to novel approaches for the treatment of schizophrenia. In this article, we review drugs that modulate ionotropic gluamate receptors and discuss their efficacy for the treatment of this often debilitating severe mental illness.

(PDF emailed within 1 workday: $29.90)

Accession: 055398726

Download citation: RISBibTeXText

PMID: 22283761

Related references

Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Targets. Cns and Neurological Disorders 1(2): 183-189, 2003

Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27(5): 826-833, 2002

Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. American Journal of Psychiatry 157(7): 1141-1149, 2000

Ionotropic receptors (IRs): chemosensory ionotropic glutamate receptors in Drosophila and beyond. Insect Biochemistry and Molecular Biology 43(9): 888-897, 2014

The effects of activation of group III metabotropic glutamate receptors in the nucleus tractus solitarius require ionotropic glutamate receptors. Society for Neuroscience Abstracts 24(1-2): 868, 1998

Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology 202(1-3): 259-273, 2008

In vivo activation of metabotropic glutamate receptors by tACPD potentiates agonist effects at ionotropic glutamate receptors. Society for Neuroscience Abstracts 18(1-2): 647, 1992

Metabotropic glutamate receptors in the trafficking of ionotropic glutamate and GABA(A) receptors at central synapses. Current Neuropharmacology 4(1): 77-86, 2008

Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Current Pharmaceutical Design 17(2): 94-102, 2011

Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology 233(13): 2425-2428, 2016

Capsaicin-induced glutamate release is implicated in nociceptive processing through activation of ionotropic glutamate receptors and group I metabotropic glutamate receptor in primary afferent fibers. Journal of Pharmacological Sciences 109(2): 233-241, 2009

Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors. Synapse 63(8): 705-709, 2009

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174(1): 39-44, 2004

Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. Cns Spectrums 12(6): 423-427, 2007

The delta2 glutamate-like receptor undergoes similar conformational changes as other ionotropic glutamate receptors. Journal of Neuroscience 29(21): 6767-6768, 2009